 Bio-Path Holdings, Inc., BPTH, a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the full year ended December 31, 2019 and provided an update on recent corporate developments. Following the successful completion of the safety testing in Stage 2 of our Phase 2 Clinical Trial of prexigebersen in Acute Myeloid Leukemia AML, we now plan to advance this program to its next stage in the first half of 2020. In addition, we filed an Investigational New Drug IND application for prexigebersen in the treatment of solid tumors including ovarian and endometrial cancer and expect to start that study later this year. 